[Research progress in liver cancer in 2025]. [PDF]
Zhonghua Gan Zang Bing Za ZhiMiao TG, Nan YM.
europepmc +1 more source
[Strategies for immunotherapy-related hepatotoxicity in liver cancer]. [PDF]
Zhonghua Gan Zang Bing Za Zhi, 2023 Zhi Y, Mao YM.
europepmc +1 more source
[ERI3 expression is elevated in hepatocellular carcinoma and correlates with poor patient prognosis]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoZhao X +8 more
europepmc +1 more source
[Strategies for liver injury caused by hepatocellular carcinoma targeted therapy]. [PDF]
Zhonghua Gan Zang Bing Za Zhi, 2023 Zhao SX, Liu SH, Nan YM.
europepmc +1 more source
Zhongshan Daxue xuebao. Yixue kexue ban, 1992 1980～1990年,作者收治原发性肝癌660例,手术切除124例(18.8％)。术后肝内复发者32例(肝内复发率25.8％),2 年以内复发者占93.8％。93.7％合并肝硬化,15.5％并发门脉高压症。复发肝癌中4例(3.2％,4/124)行再切除,术后生存平均26.8月;22例行B超引导肝癌复发灶无水酒精注射术,术后8例死亡,平均生存8.5月;10例行肝动脉栓塞化疗或肝动脉结扎及插管化疗,术后生存平均16.8月,对照组仅4.5月。复发癌再次外科治疗以再切除术为首选(术后生存26.8～42.6月 ...
doaj
[HDAC2-mediated H3K27 acetylation promotes the proliferation and migration of hepatocellular carcinoma cells]. [PDF]
Beijing Da Xue Xue Bao Yi Xue BanTang S +5 more
europepmc +1 more source
[Deubiquitinating enzyme MINDY1 is an independent risk factor for the maintenance of stemness and poor prognosis in liver cancer cells]. [PDF]
Zhonghua Gan Zang Bing Za Zhi, 2023 Xia BL +5 more
europepmc +1 more source
[Novel research horizon for liver transplantation management model in hepatocellular carcinoma based on the tumor-donor liver-recipient]. [PDF]
Zhonghua Gan Zang Bing Za ZhiXu SJ, Xu YY, Xu X.
europepmc +1 more source
[Establishment of a database for liver cancer ablation and its clinical research value]. [PDF]
Zhonghua Gan Zang Bing Za ZhiLuo YC, Lang ML, Liang P, Yu J.
europepmc +1 more source
[Factors affecting tumorigenicity in liver cancer xenografts]. [PDF]
Zhonghua Gan Zang Bing Za ZhiChai MY +6 more
europepmc +1 more source